Use of Tricyclic Antidepressants in the Management of Diabetic Neuropathic Pain : A Systematic Review of Randomized Controlled Trials and Primary Studies
The International Journal of Medical Science and Health Research · 21.07.2026 · 48 (4) · 187-241
DOI: 10.70070/prasck26 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 21.07.2026. Verfasst von David William Brian Iskandar. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Diabetic neuropathic pain (DNP) is one of the most prevalent and debilitating complications of diabetes mellitus, affecting 15–26% of diabetic patients globally. Tricyclic antidepressants (TCAs) — including amitriptyline, imipramine, nortriptyline, and desipramine — have been utilized as analgesic agents through mechanisms involving norepinephrine and serotonin reuptake inhibition, sodium channel blockade, and central pain modulation. Despite decades of clinical use, a comprehensive primary-evidence synthesis exclusively evaluating TCA pharmacotherapy across the full spectrum of clinical outcomes in DNP has not been recently performed. This systematic review consolidates all available randomized controlled trials and primary observational evidence on TCA pharmacotherapy in DNP.
Methods
The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible primary study designs: randomized controlled trials (RCTs), cohort studies, case-control studies, cross-sectional studies, and observational prospective/retrospective studies.
Results
Fifteen primary studies met inclusion criteria for the Study Characteristics Table (Table 2): 13 RCTs and 2 prospective observational/open-label trials, enrolling 1,842 participants across multiple continents. Additional supporting evidence from 7 verified systematic reviews and meta-analyses is incorporated in outcome analyses and discussion. Amitriptyline achieved moderate-to-greater pain relief in 55–74% vs. 20–41% placebo. Desipramine demonstrated equivalent analgesic efficacy to amitriptyline. Imipramine yielded NNT 1.4 (optimal dose) to 2.4.1,2,3 The landmark OPTION-DM trial (Tesfaye 2022) confirmed NRS reduction from 6.6 to 3.3 (p
Zitieren
APA
Iskandar, D. W. B. (2026). Use of Tricyclic Antidepressants in the Management of Diabetic Neuropathic Pain : A Systematic Review of Randomized Controlled Trials and Primary Studies. The International Journal of Medical Science and Health Research, 48(4), 187-241. https://doi.org/10.70070/prasck26
Vancouver
Iskandar DWB. Use of Tricyclic Antidepressants in the Management of Diabetic Neuropathic Pain : A Systematic Review of Randomized Controlled Trials and Primary Studies. The International Journal of Medical Science and Health Research. 2026;48(4):187-241. doi:10.70070/prasck26
BibTeX
@article{Iskandar2026,
author = {Iskandar, David William Brian},
title = {Use of Tricyclic Antidepressants in the Management of Diabetic Neuropathic Pain : A Systematic Review of Randomized Controlled Trials and Primary Studies},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {48},
number = {4},
pages = {187--241},
doi = {10.70070/prasck26}
}
EUVIMED